FDA Grand Rounds: Why FDA authorized the marketing of the IQOS heated tobacco product as “appropriate for the protection of the public health”
October 10, 2019
WO 2: 2047
The FDA Grand Rounds is webcast monthly to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.
In 2009, the Family Smoking Prevention and Tobacco Control Act (TCA) was signed by the President "to protect the public health by providing the Food and Drug Administration with certain authority to regulate tobacco products…" The TCA requires FDA premarket review of new tobacco products and evaluation of whether marketing the product(s) is "appropriate for the protection of public health."
This population health standard, directing FDA to assess impact on the population as a whole and not only individual product users, required creation of a new FDA review process. Questions arise regarding how to minimize the risks while maximizing the possible benefits of allowing new tobacco products or modified risk products on the market. The scientific review process is complex and involves data from a breadth of scientific disciplines.
The Center for Tobacco Products (CTP) is responsible for carrying out the TCA. Our mission is to protect Americans from tobacco-related death and disease by regulating the manufacture, distribution, and marketing of tobacco products and by educating the public, especially young people, about tobacco products and the dangers their use poses to themselves and other. After a brief introduction to CTP, this presentation will provide a description of the IQOS heated tobacco products and a summary of the applications. The specific requirements of the TCA and the criteria for denying marketing authorization will be described as well as a brief discussion of FDA's understanding of what it means to be "appropriate for the protection of public health." Finally, the presentation will conclude with an explanation of the rationale for FDA's decision regarding IQOS and how this may impact future Premarket Tobacco Applications and tobacco control.
- Family Smoking Prevention and Tobacco Control Act – An Overview; https://www.fda.gov/tobacco-products/rules-regulations-and-guidance/family-smoking-prevention-and-tobacco-control-act-overview
- IQOS Premarket Tobacco Application Technical Project Lead Review; IQOS PMTA TPL Review (redacted). https://www.fda.gov/media/124247/download
- The Public Health Rationale for Recommended Restrictions on New Tobacco Product Labeling, Advertising, Marketing, and Promotion. https://www.fda.gov/media/124174/download
- Draft Guidance, Applications for Premarket Review of New Tobacco Products. https://www.fda.gov/media/81821/download
- Final Guidance, Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS), https://www.fda.gov/media/127853/download
- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health
- Describe the Center for Tobacco Products and its’ responsibilities with respect to the Family Smoking Prevention and Tobacco Control Act
- Explain the Pre-market Tobacco Product Application review process
- Describe the IQOS heated tobacco products
- Discuss the scientific review process as it relates specifically to the IQOS products and explain why FDA believes marketing of IQOS products is appropriate for the protection of public health
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
Lecture 1 October 10, 2019
Time | Topic | Speaker |
---|---|---|
12:00 - 1:00 PM EDT | Why FDA authorized the marketing of the IQOS heated tobacco product as “appropriate for the protection of the public health” | Priscilla Callahan-Lyon, MD |
Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Callahan-Lyon, Priscilla, MD, Senior Science Advisor, Office of the Center Director, CTP, FDA Center for Tobacco Products - nothing to disclose
Planning Committee
- Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
- KEMPF, LUCAS, MD - nothing to disclose
- Lee, Christine, PhD, PharmD, General Health Scientist, FDA - nothing to disclose
- Pfundt, Tiffany, PharmD, Program Coordinator, FDA/CDER/OTBB - nothing to disclose
- Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose
CE Consultation and Accreditation Team
- Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary; therefore refunds are not applicable.